Dawnrays Pharmaceutical Holdings Ltd. (HK:2348)
:2348
Top Page
Dawnrays Pharmaceutical Holdings Ltd.
(2348)
Select Model
Select Model
Rating:66Neutral
Price Target:
HK$1.50
â–²(25.00% Upside)
Action:ReiteratedDate:10/25/25
The overall score of 66 for Dawnrays Pharmaceutical is driven primarily by strong financial performance, with high profitability and a solid balance sheet. However, concerns over declining revenue and weak cash flow growth temper the outlook. A reasonable valuation with an attractive dividend yield provides some support, while technical indicators remain neutral.
Positive Factors
Strong Profit Margins
High gross profit margins indicate efficient cost management, allowing the company to maintain profitability even in challenging revenue environments.
Negative Factors
Declining Revenue
A decline in revenue growth can indicate challenges in market demand or competitive pressures, potentially impacting future profitability and market position.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profit Margins
High gross profit margins indicate efficient cost management, allowing the company to maintain profitability even in challenging revenue environments.
Read all positive factors
Dawnrays Pharmaceutical Holdings Ltd. (2348) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.74B
Dividend Yield5.16%
Average Volume (3M)355.07K
Price to Earnings (P/E)7.9
Beta (1Y)0.32
Revenue Growth2.89%
EPS Growth-68.83%
CountryHK
Employees1,183
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.08
Shares Outstanding1,503,605,000
10 Day Avg. Volume239,600
30 Day Avg. Volume355,066
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.52
Price to Sales (P/S)1.63
P/FCF Ratio38.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Dawnrays Pharmaceutical Holdings Ltd. Business Overview & Revenue Model
Company Description
Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines...
How the Company Makes Money
Dawnrays Pharmaceutical Holdings Ltd. generates revenue through multiple streams, including the sale of prescription medications and OTC products. The company benefits from a diversified product portfolio, which allows it to cater to various marke...
Dawnrays Pharmaceutical Holdings Ltd. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
85
Very Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.11B | 1.06B | 1.15B | 1.28B | 1.17B | 1.02B |
| Gross Profit | 509.46M | 577.63M | 641.52M | 766.68M | 675.36M | 545.55M |
| EBITDA | 226.47M | 280.49M | 498.94M | 505.19M | 433.89M | 395.71M |
| Net Income | 176.47M | 564.94M | 326.00M | 358.06M | 358.18M | 268.13M |
Balance Sheet | ||||||
| Total Assets | 3.88B | 4.01B | 3.62B | 3.67B | 3.34B | 2.90B |
| Cash, Cash Equivalents and Short-Term Investments | 1.62B | 1.37B | 1.07B | 993.04M | 830.22M | 932.11M |
| Total Debt | 9.16M | 34.72M | 120.53M | 8.41M | 23.52M | 2.95M |
| Total Liabilities | 579.69M | 682.61M | 763.42M | 1.02B | 941.70M | 720.14M |
| Stockholders Equity | 3.30B | 3.32B | 2.85B | 2.64B | 2.38B | 2.17B |
Cash Flow | ||||||
| Free Cash Flow | 195.90M | 44.58M | 126.39M | 229.90M | 80.07M | 163.80M |
| Operating Cash Flow | 250.73M | 220.20M | 338.40M | 434.27M | 393.14M | 302.90M |
| Investing Cash Flow | -263.09M | 205.17M | -387.57M | -175.01M | -284.20M | 26.45M |
| Financing Cash Flow | -285.41M | -189.44M | 2.07M | -92.70M | -129.75M | -327.70M |
Dawnrays Pharmaceutical Holdings Ltd. Technical Analysis
Positive
1.20
Price Trends
1.16
Negative
1.18
Negative
1.21
Negative
Market Momentum
-0.01
Negative
54.37
Neutral
67.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2348, the sentiment is Positive. The current price of 1.2 is above the 20-day moving average (MA) of 1.13, above the 50-day MA of 1.16, and below the 200-day MA of 1.21, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 54.37 is Neutral, neither overbought nor oversold. The STOCH value of 67.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2348.
Dawnrays Pharmaceutical Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$7.37B | 6.31 | 11.90% | 5.80% | -20.64% | -25.39% | |
72 Outperform | HK$14.03B | 5.21 | 24.04% | 3.93% | 19.05% | 13.68% | |
69 Neutral | HK$2.38B | 5.13 | 12.97% | 15.40% | -1.88% | 17.57% | |
66 Neutral | HK$1.74B | 7.90 | 5.33% | 5.16% | 2.89% | -68.83% | |
54 Neutral | HK$9.06B | -28.37 | -1.64% | 3.66% | -9.58% | -128.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$13.16B | 22.81 | -1.84% | 0.87% | 19.21% | -115.91% |
* Healthcare Sector Average
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.16
0.14
13.73%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.80
0.08
4.59%
HK:0460
Sihuan Pharmaceutical Holdings Group
1.41
0.85
153.60%
HK:1681
Consun Pharmaceutical Group Ltd.
17.07
9.04
112.68%
HK:2633
Jacobson Pharma Corporation Limited
1.25
0.27
27.55%
HK:2877
China Shineway Pharmaceutical Group Limited
9.76
2.90
42.27%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.